RE:Manipulation.Definitely appreciate the optimistic thoughts, but all pure speculation. A more realistic approach is this company can't generate any revenue, and competitors in markets it was hoping to dominate (Europe) have all caught up with GMP certifications (somaipharma.eu as an example) over the past two years. MediPharm has nothing exceptional going for it. Why anybody would buy this pig instead of a dividend paying ETF or stock is beyond me.